A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single AscendingDose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (PODL-dopa) Administered in the Presence of Benserazide to L-dopa ResponsiveParkinsons Disease Patients

Trial Profile

A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single AscendingDose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (PODL-dopa) Administered in the Presence of Benserazide to L-dopa ResponsiveParkinsons Disease Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Levodopa (Primary) ; Benserazide
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Acronyms THOR201
  • Sponsors Impel NeuroPharma
  • Most Recent Events

    • 29 May 2018 Status changed from not yet recruiting to recruiting.
    • 29 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top